​醫療資訊部落格

pebmrolizmab臨床實驗資訊

October 5, 2015

臨床實驗的資訊:
實驗名:A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

概要:This is a study of pembrolizumab for advanced gastric or gastroesophageal junction adenocarcinoma; pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-naïve; pembrolizumab will also be evaluated as combination therapy with cisplatin and 5-Fluorouracil (5-FU) in treatment-naïve participants. The primary study hypothesis is that pembrolizumab will provide a clinically meaningful overall response rate.

簡單介紹:針對胃癌,以及復發患者進行pembrolizumab的臨床實驗。如果已經接受治療的話,就單純使用pebmrolizumab,沒有的話,可能使用5FU、順鉑等等配合pebmrolizumab去進行。相關更詳盡的資訊請參考

 

https://clinicaltrials.gov/ct2/show/NCT02335411?

 

 

 

Tags:

Share on Facebook
Share on Twitter
Please reload

​特輯

日本各地醫院臨床計畫

December 31, 2014

1/1
Please reload

最新文章
Please reload

每月封存
Please reload

TAG檢索
SNS
  • Instagram
  • 醫療助手臉書粉絲團

Copyright© 2015 新義豊株式会社 All rights reserved.